AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17878469 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters
Number of subjects: 0
Study 15792748 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive thoracic epidural (TE) analgesia
Number of subjects: 56
Study 15792748 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 56
Study 12148095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CT angiography (CTA)
Number of subjects: 80
Study 12148095 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial digital subtraction angiography (DSA)
Number of subjects: 80
Study 10532976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid laser treatment
Number of subjects: 45
Study 10532976 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 45
Study 8593974 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 300 mg twice daily
Number of subjects: 117
Study 8593974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 1592254 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention
Number of subjects: 0
Study 1592254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2869616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d.
Number of subjects: 1741
Study 2869616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study 30800121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (100,000 IU every 15 days for 3 months)
Number of subjects: 38
Study 30800121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30350761 — intervention group
Group type: COMPARATOR
Intervention: Interactive 24-h recall (i-24-HR)
Number of subjects: 132
Study 30350761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 132
Study 30350761 — intervention group
Group type: COMPARATOR
Intervention: Weighed food records
Number of subjects: 132
Study 26314086 — intervention group
Group type: EXPERIMENTAL
Intervention: DAIRYCHOC
Number of subjects: 8
Study 26314086 — intervention group
Group type: EXPERIMENTAL
Intervention: SOYCHOC
Number of subjects: 8
Study 26314086 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMPCHOC
Number of subjects: 8
Study 26314086 — intervention group
Group type: EXPERIMENTAL
Intervention: MILK
Number of subjects: 8
Study 26314086 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 8
Study 22933811 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed audiovisual attention
Number of subjects: 0
Study 22933811 — intervention group
Group type: COMPARATOR
Intervention: Focused visual attention
Number of subjects: 0
Study 20529984 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-dose nefopam (50 ng/mL)
Number of subjects: 7
Study 20529984 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose nefopam (100 ng/mL)
Number of subjects: 7
Study 20529984 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 7
Study 18824706 — intervention group
Group type: EXPERIMENTAL
Intervention: IROX (irinotecan 200 mg/m² plus oxaliplatin 85 mg/m²)
Number of subjects: 628
Study 18824706 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan alone (350 mg/m²)
Number of subjects: 628
Study 18824706 — intervention group
Group type: EXPERIMENTAL
Intervention: IROX
Number of subjects: 628
Study 18824706 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan alone
Number of subjects: 628
Study 15619410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 13
Study 12162939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 12162939 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 0
Study 9459088 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified FSH preparation (9 patients, 35 follicular fluid samples)
Number of subjects: 18
Study 9459088 — intervention group
Group type: COMPARATOR
Intervention: FSH-dominant human menopausal gonadotropin (hMG) preparation (9 patients, 34 samples)
Number of subjects: 18
Study 8182402 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC) therapy with intravenous heparin infusion for at least 6 days and oral AC therapy for 3 months
Number of subjects: 87
Study 8182402 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant (non-AC) therapy
Number of subjects: 87
Study 8182402 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC) therapy
Number of subjects: 87
Study 8182402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AC and non-AC groups
Number of subjects: 87
Study 3234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat/high malto‐dextrin formula (2.6 g fat/100 ml, 8.1 g carbohydrate/100 ml, 2.8 g malto‐dextrin/100 ml)
Number of subjects: 11
Study 3234438 — intervention group
Group type: COMPARATOR
Intervention: High fat/low malto‐dextrin formula (3.6 g fat/100 ml, 7.3 g carbohydrate/100 ml, 1.9 g malto‐dextrin/100 ml)
Number of subjects: 11
Study 3234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 11
Study 3234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat formula
Number of subjects: 11
Study 29153485 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300U/mL (Gla‐300) at 0.4U/kg/day
Number of subjects: 48
Study 29153485 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300U/mL (Gla‐300) at 0.6U/kg/day
Number of subjects: 48
Study 29153485 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec 100U/mL (Deg‐100) at 0.4U/kg/day
Number of subjects: 48
Study 29153485 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec 100U/mL (Deg‐100) at 0.6U/kg/day
Number of subjects: 48
Study 28211600 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored, pragmatically delivered progressive interventions
Number of subjects: 41
Study 28211600 — intervention group
Group type: COMPARATOR
Intervention: Prescriptive sham to minimally progressive interventions
Number of subjects: 41
Study 24792229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 283
Study 24792229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 22676626 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine
Number of subjects: 12194
Study 22676626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12194
Study 20096138 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 40 mg) plus B12 (0.5 mg), B6 (25 mg) and folic acid (2 mg)
Number of subjects: 300
Study 20096138 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 to 40 mg) plus placebo
Number of subjects: 300
Study 19008063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual flow injection protocol with saline chaser containing 20% contrast media
Number of subjects: 106
Study 19008063 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure for contrast-enhanced imaging of coronary arteries
Number of subjects: 106
Study 16607927 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 171
Study 16607927 — intervention group
Group type: EXPERIMENTAL
Intervention: FGIR
Number of subjects: 171
Study 16607927 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 171
Study 16607927 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRI
Number of subjects: 171
Study 16607927 — intervention group
Group type: COMPARATOR
Intervention: Fasting and 2-hour insulin levels
Number of subjects: 171
Study 12580984 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg day(-1)
Number of subjects: 12
Study 12580984 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg day(-1)
Number of subjects: 12
Study 8825162 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH+) through partial zona dissection (PZD)
Number of subjects: 120
Study 8825162 — intervention group
Group type: COMPARATOR
Intervention: No assisted hatching (AH‐)
Number of subjects: 120
Study 7682266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 20,000 U/kg after induction, 20,000 U/kg added to the prime, and 20,000 U/kg every hour during cardiopulmonary bypass (low-dose regimen)
Number of subjects: 42
Study 7682266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 35,000 U/kg after induction followed by an infusion of 10,000 U/kg.min until the end of the operation and 35,000 U/kg added to the prime (high-dose regimen)
Number of subjects: 42
Study 7682266 — intervention group
Group type: COMPARATOR
Intervention: No aprotinin used (control)
Number of subjects: 42
Study 7682266 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 42
Study 7682266 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (low-dose aprotinin)
Number of subjects: 42
Study 3514480 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study 3514480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 29574443 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CR (2 weeks post-surgery)
Number of subjects: 140
Study 29574443 — intervention group
Group type: COMPARATOR
Intervention: Usual care CR (6 weeks post-surgery)
Number of subjects: 140
Study 27893864 — intervention group
Group type: EXPERIMENTAL
Intervention: One4All intervention (rapid point‐of‐care HIV screening, CD4 and viral load testing with same‐day results and linkage to counselling)
Number of subjects: 12
Study 27893864 — intervention group
Group type: EXPERIMENTAL
Intervention: One4All intervention
Number of subjects: 12
Study 27893864 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 12
Study 24606088 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iv methylprednisolone
Number of subjects: 80
Study 24606088 — intervention group
Group type: COMPARATOR
Intervention: Daily iv methylprednisolone
Number of subjects: 80
Study 21868186 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person aftercare
Number of subjects: 0
Study 21868186 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone aftercare
Number of subjects: 0
Study 21868186 — intervention group
Group type: COMPARATOR
Intervention: No-active aftercare
Number of subjects: 0
Study 20683501 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (25-150 mg equivalents)
Number of subjects: 0
Study 20683501 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (25-100 mg equivalents)
Number of subjects: 0
Study 20683501 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 0
Study 20683501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45mg/day)
Number of subjects: 44
Study 18778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000-2000mg/day)
Number of subjects: 44
Study 15754408 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection with postoperative chemotherapy
Number of subjects: 179
Study 15754408 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 179
Study 15754408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 179
Study 15754408 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 179
Study 12066723 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK group (500 ml of 50% dextrose solution containing 100 IU insulin and potassium 80 mmol infused at 0.75 ml kg(‐1) h(‐1))
Number of subjects: 42
Study 12066723 — intervention group
Group type: COMPARATOR
Intervention: Non-GIK group (5% dextrose solution infused at the same rate)
Number of subjects: 42
Study 10522560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia
Number of subjects: 418
Study 8808179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine alone (750 mg)
Number of subjects: 27
Study 8808179 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine in combination with artemether (300 mg, given 24 hours prior)
Number of subjects: 27
Study 1791605 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 4736
Study 1791605 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4736
Study 393728 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 102
Study 393728 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 102
Study 393728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 31062903 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month home-based behaviour change intervention incorporating goal setting, self-monitoring and feedback, with motivational interviewing (n = 201)
Number of subjects: 401
Study 31062903 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group (n = 200)
Number of subjects: 401
Study 27995521 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus Betamethasone Dipropionate Aerosol Foam
Number of subjects: 35
Study 27995521 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-Valerate-Medicated Plaster
Number of subjects: 35
Study 26055848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (attended two 6-session, 12-week group education modules)
Number of subjects: 698
Study 26055848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 698
Study 26055848 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 698
Study 23295710 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 102
Study 23295710 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 102
Study 21437436 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal row carpectomy
Number of subjects: 20
Study 21437436 — intervention group
Group type: COMPARATOR
Intervention: Four-corner fusion
Number of subjects: 20
Study 18788990 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (70 mg) for 6 months
Number of subjects: 50
Study 18788990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16785776 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 10
Study 16785776 — intervention group
Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 10
Study 14556830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 8
Study 14556830 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer by clinical touch alone
Number of subjects: 8
Study 10810399 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively (Group A)
Number of subjects: 126
Study 10810399 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively plus UFT orally at a dose of 400 mg daily for one year (Group B)
Number of subjects: 126
Study 8857073 — intervention group
Group type: EXPERIMENTAL
Intervention: FK613 5 mg
Number of subjects: 0
Study 8857073 — intervention group
Group type: EXPERIMENTAL
Intervention: FK613 20 mg
Number of subjects: 0
Study 8857073 — intervention group
Group type: EXPERIMENTAL
Intervention: FK613 40 mg twice daily for 6.5 days
Number of subjects: 0
Study 8857073 — intervention group
Group type: EXPERIMENTAL
Intervention: FK613 30 mg or more
Number of subjects: 0
Study 8857073 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel-type formulation of FK613
Number of subjects: 0
Study 8857073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study 1739560 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% oxygen by face mask
Number of subjects: 35
Study 1739560 — intervention group
Group type: COMPARATOR
Intervention: 21% oxygen by face mask
Number of subjects: 35
Study 6712318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic resection
Number of subjects: 35
Study 6712318 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal lavation
Number of subjects: 35
Study 28691577 — intervention group
Group type: EXPERIMENTAL
Intervention: Five practice tests
Number of subjects: 0
Study 28691577 — intervention group
Group type: COMPARATOR
Intervention: One practice test
Number of subjects: 0
Study 28691577 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial length increase
Number of subjects: 0
Study 26427984 — intervention group
Group type: EXPERIMENTAL
Intervention: vincristine-carboplatin
Number of subjects: 55
Study 26427984 — intervention group
Group type: COMPARATOR
Intervention: etoposide-carboplatin
Number of subjects: 55
Study 25637937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (n = 578)
Number of subjects: 1147
Study 25637937 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 569)
Number of subjects: 1147
Study 25637937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan with ACE inhibitors and β-blockers
Number of subjects: 1147
Study 25637937 — intervention group
Group type: COMPARATOR
Intervention: Control with ACE inhibitors and β-blockers
Number of subjects: 1147
Study 24119552 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention group (education package encouraging reduction in sitting behaviors)
Number of subjects: 0
Study 24119552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desk intervention group (education package + adjustable sit-stand desk)
Number of subjects: 0
Study 24119552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 21843836 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (three sets of eight repetitions of quadriceps resistance exercise at 70% of one repetition maximum, supervised by physiotherapists)
Number of subjects: 40
Study 21843836 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard doses of oral corticosteroids and physiotherapy limited to airway clearance techniques and breathing exercises)
Number of subjects: 40
Study 21843836 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 40
Study 17604664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg twice daily
Number of subjects: 528
Study 17604664 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 330 microg twice daily
Number of subjects: 528
Study 17315803 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite
Number of subjects: 0
Study 17315803 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% Ethylenediamintetraacetic acid (EDTA)
Number of subjects: 0
Study 17315803 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 17315803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT + TPH resin-based composite
Number of subjects: 0
Study 17315803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L-Pop + F2000
Number of subjects: 0
Study 14743986 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up and static stretch
Number of subjects: 56
Study 14743986 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretch only
Number of subjects: 56
Study 14743986 — intervention group
Group type: COMPARATOR
Intervention: Warm-up only
Number of subjects: 56
Study 14743986 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 10919732 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 184
Study 10919732 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU d‐alpha‐tocopheryl acetate/day)
Number of subjects: 184
Study 10919732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamins C and E
Number of subjects: 184
Study 10919732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 8808724 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg i.v. bolus of ondansetron
Number of subjects: 60
Study 8808724 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg i.v. granisetron
Number of subjects: 60
Study 8808724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg i.v. tropisetron
Number of subjects: 60
Study 8808724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further antiemetic therapy)
Number of subjects: 60
Study 1318390 — intervention group
Group type: EXPERIMENTAL
Intervention: P/B (PAK and sodium bicarbonate)
Number of subjects: 8
Study 1318390 — intervention group
Group type: EXPERIMENTAL
Intervention: PAK (Pyridoxine-alpha-ketoglutarate)
Number of subjects: 8
Study 1318390 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC (Sodium bicarbonate and placebo)
Number of subjects: 8
Study 1318390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.30 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (0 mg/kg) + Diazepam (0.15 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (0 mg/kg) + Diazepam (0.30 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) + Diazepam (0.15 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) + Diazepam (0.30 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) + Diazepam (0.15 mg/kg)
Number of subjects: 108
Study 3936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) + Diazepam (0.30 mg/kg)
Number of subjects: 108